Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 13/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21835797 | 0.86 | MAOB (0.54) | HPGDSHDAC2TRPV1 | |
| SCHEMBL21835788 | 0.86 | HDAC2 (0.52) | MGAMHPGDSHDAC2HCAR3TRPV1 | |
| SCHEMBL1756743 | 0.76 | MEN1 (0.45) | HCAR3CFTR | |
| SCHEMBL15681577 | 0.76 | HDAC2 (0.65) | MGAMHPGDSHDAC2EGLN1CFTR | |
| SCHEMBL25301722 | 0.76 | TERT (0.54) | MGAMHPGDSHCAR3CFTR | |
| SCHEMBL21835781 | 0.76 | HDAC2 (0.58) | HPGDSHDAC2 | |
| SCHEMBL21835787 | 0.75 | HCAR3 (0.55) | MGAMHPGDSHCAR3 | |
| SCHEMBL5004759 | 0.74 | PPARA (0.48) | — | |
| SCHEMBL17075550 | 0.74 | KDM4E (0.56) | HDAC2HCAR3EGLN1 | |
| SCHEMBL21835784 | 0.73 | MAOB (0.55) | HPGDSHDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858919-B2 | HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858919-B2 | HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858919-B2 | HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220033388-A1 | HDAC1,2 Inhibitors | REGENACY PHARMACEUTICALS, LLC | 2022-02-03 | — | — | US | disclosed |
| US-20220033388-A1 | HDAC1,2 Inhibitors | REGENACY PHARMACEUTICALS, LLC | 2022-02-03 | — | — | US | disclosed |
| EP-3856174-A1 | HDAC1,2 INHIBITORS | Regenacy Pharmaceuticals, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020068950-A1 | HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC (US) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858919-B2 | HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | MGAM 3371/4885HPGDS 2233/4885HDAC2 2/4885 |
| US-20220033388-A1 | HDAC1,2 Inhibitors | HDAC1, HDAC2, HDAC11 | MGAM 3371/4885HPGDS 2233/4885HDAC2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.